# IQVIA

the largest commercialization partner for named-patient and patient-support programs, drawing on data from more than 5,000 supported launches and the LAAD dataset; on 13 May 2026 it expanded its AI-enabled biosimilar collaboration with Kexing Biopharm (688136.SH) spanning clinical,…

Source: https://en.bioecon.ru/companies/iqvia/
Updated: 2026-08-15

- Country: United States
- Ticker: NYSE: IQV

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Headquarters | Durham, North Carolina, United States | https://umbrex.com/resources/company-profiles/iqvia/ |
| Headcount | approximately 93,000 employees | https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Issues-Full-Year-2026-Guidance/default.aspx, https://www.iqvia.com/about-us, https://www.sec.gov/Archives/edgar/data/1478242/000162828026012899/ars_2025.pdf |
| Revenue | $16.31 billion in 2025 | https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Issues-Full-Year-2026-Guidance/default.aspx |
| Certification | GCLP, GLP, AAALAC, CCAC, OLAW, and BBL (location specific) | https://labs.iqvia.com/vaccines-site-laval, https://labs.iqvia.com/vaccines-site-marburg |
| Production site | Various global laboratory locations including Durham, NC; Indianapolis, IN; Ithaca, NY; Valencia, CA; Marietta, GA; Laval, Quebec; Marburg, Germany; and Beijing, China [medium confidence] | https://labs.iqvia.com/locations, https://labs.iqvia.com/vaccines-site-laval, https://labs.iqvia.com/vaccines-site-marburg, https://labs.iqvia.com/visitor-guide/beijing |

Independent sources: sec.gov, umbrex.com

## Technologies

- [Medical-affairs platforms (CME, MSL)](https://en.bioecon.ru/technology/medical-affairs-platforms/)
- [Named-patient programs & compassionate use](https://en.bioecon.ru/technology/named-patient-compassionate-use/)